Medigene AG
MDGEF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -80.7% | 198.6% | 30.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 72.8% | 23.7% | 54.2% | 3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -267.6% | -29.2% | -100.5% | -339.9% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -268.1% | -26.7% | -95.4% | -360.8% |
| EPS | -1.32 | -0.64 | -0.77 | -2.23 |
| % Growth | -106.3% | 16.9% | 65.5% | – |
| EPS Diluted | -1.32 | -0.64 | -0.77 | -2.23 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -256% | 42% | -62.2% | -269.1% |